Mar 22,2023

Dario Announces Strategic Partnership with Amwell to Expand Access to its Cardiometabolic Digital Therapeutic Solution

DarioHealth Corp announced today a strategic partnership with Amwell to deliver its cardiometabolic solution to Amwell customers. Dario's solution will be available through Amwell beginning in the second half of 2023. The agreement is part of Dario's strategy to partner with market leading strategic partners to accelerate adoption of Dario's solutions by making the Dario solution available to existing Amwell customers. Members living with cardiometabolic health concerns such as diabetes, high blood pressure and weight management challenges will have access to Dario's proven and highly personalized digital solution to help better manage their condition and improve outcomes between visits with clinicians practicing on the Amwell platform. Members can access Dario's solutions directly through Amwell's digital care delivery enablement platform to support ease of engagement.

COLLABORATION PARTNERSHIP

#institution

#dtx

#telehealth

View Analyst & Ambassador Comments
Go to original news
Feb 22,2023 TOP STORY

Dawn Health, Novartis partner to develop chronic condition management tools

Copenhagen-based digital health company Dawn Health announced a strategic partnership with pharma giant Novartis to develop a chronic condition management platform. Under the collaboration, Dawn and Novartis will build remote monitoring and management tools for chronic conditions where they see unmet need and concerns around disease progression, like multiple sclerosis, hypertension, cardiovascular disease and breast cancer. The platform will include patient mobile apps, symptom monitoring, digital biomarkers, clinical decision support services and virtual clinic offerings geared toward specific diseases and conditions.

COLLABORATION PARTNERSHIP

#r&d

#rpm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jan 03,2023

Dario Achieves Goal of 100 Business-to-Business Contracts in 2022

DarioHealth Corp. announced today that a large Northeast U.S. supermarket chain selected Dario to help improve the cardiometabolic health of its employees beginning in the first quarter of 2023, marking the Company reaching 100 enterprise contracts signed. The Employer selected Dario's cardiometabolic suite to support employees living with diabetes, high blood pressure and weight management needs using a holistic approach that combines connected devices, smart technologies and human support to improve overall health.

PRODUCT

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Dec 13,2022

A New Study From Hello Heart Shows Surprising Findings on Walking Patterns and Heart Health

Hello Heart today announced new data on how minor lifestyle and behavioral changes can have a significant impact on improving heart health. The findings were collected from 6,000 Hello Heart users nationwide over six months. According to this new data, it’s not as daunting to make a positive impact on systolic blood pressure as people may think.

CLINICAL STUDY

#mobile app

#connected device

View Analyst & Ambassador Comments
Go to original news
Feb 24,2020

DarioHealth Digital Diabetes Management System is Now Available at Albertsons

DarioHealth announced today the launch of its digital therapeutics solution for managing chronic diseases such as diabetes and hypertension on Albertsons Marketplace. Albertsons Companies is one of the largest retailers in the United States, with more than 2,000 grocery stores under well-known banners such as Albertsons, Safeway, Vons, Jewel-Osco, Shaw's, Acme, Tom Thumb, Randalls, United Supermarkets, Pavilions, Star Market, Haggen and Carrs. Through more than 1,700 in-store pharmacies across the country. Dario™ will be offering its innovative "Membership-in-a-Box" package which is designed to reach consumers with chronic conditions such as diabetes who shop at retail stores.

COLLABORATION PARTNERSHIP

#institution

#mobile app

#connected device

View Analyst & Ambassador Comments
Go to original news
Mar 11,2020

CVS Caremark adds five companies to digital health platform, including Hello Heart

Hello Heart, and a handful of other digital health companies will join CVS Health’s platform for PBM clients. CVS announced it would add five companies to its Point Solutions Management Service, a service it launched last year to make it easier for CVS Caremark clients to contract with third-party apps and monitor their performance. CVS said it plans to add more digital health solutions in the future, including in weight loss, women’s health, mental health, and other categories.

COLLABORATION PARTNERSHIP

#institution

#mobile app

#connected device

View Analyst & Ambassador Comments
Go to original news
Mar 12,2020

Livongo Expands Relationship with CVS Health, Now Part of Chronic Condition Management Platform within Point Solutions Service

Livongo (Nasdaq: LVGO), the leading Applied Health Signals company empowering people with chronic conditions to live better and healthier lives, today announced that it is available through the CVS Health Point Solutions Management service. Point Solutions Management is a full service offering for CVS Caremark pharmacy benefit management (PBM) clients to contract, onboard, and manage health and care solutions including Livongo’s Diabetes, Hypertension, Weight Management, and Diabetes Prevention programs.

COLLABORATION PARTNERSHIP

#institution

#coaching

#connected device

View Analyst & Ambassador Comments
Go to original news
Apr 09,2020

CureApp in Partnership with Jichi University of Medicine Launches the Phase 3 Clinical Trial for Hypertension Digital Therapeutics

CureApp, Inc. (Headquarters: Chuo-ku, Tokyo; President and CEO: Kohta Satake, MD) has launched a phase 3 multicenter randomized controlled study of Digital Therapeutics in the treatment of hypertension in Japan with a number of partners, including Kazuomi Kario, MD, professor of the Division of Cardiovascular Medicine, School of Medicine, Jichi Medical University , Ph.D. The study will evaluate the effectiveness and safety of Digital Therapeutics in patients with essential hypertension who have not yet been treated with oral antihypertensive drugs.

PRODUCT

#mobile app

#software

View Analyst & Ambassador Comments
Go to original news
Apr 29,2020

DarioHealth Expands Remote Care Offering With Integration of Full-Service Telemedicine

DarioHealth Corp. (Nasdaq: DRIO), a pioneer in global digital therapeutics (DTx), announced today a new partnership with value-based telemedicine provider MediOrbis to expand Dario's existing service offering with a full suite of telemedicine capabilities for its 50,000 active users. The decision to expand Dario's remote care services is driven by the increased risk for COVID-19 complications faced by Dario's 50,000 users who depend on Dario's digital platform to manage chronic conditions like diabetes, hypertension and obesity.

COLLABORATION PARTNERSHIP

#product & service

#telehealth

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 15,2020

DarioHealth Presents New Studies Demonstrating Sustained Improvements in Blood Glucose and Blood Pressure Control

DarioHealth Corp. (Nasdaq: DRIO), a leading global digital therapeutics (DTx) company, presented the results of two new studies at the American Diabetes Association's (ADA) 80th Scientific Sessions that showed sustained improvements in blood glucose levels and blood pressure among users of its digital therapeutic platform for chronic diseases. In the first study, Dario conducted a twelve-month retrospective analysis of 9,200 non-insulin treated Type-2 diabetes (T2D) users of the Dario digital therapeutic platform for chronic disease. A subgroup of users who participated in hypertension management were also evaluated. Key results included the following: The average ratio of high blood glucose events (180-400 mg/dL) was reduced by 26% and sustained during the full year, and 71% of members using the hypertension therapeutic succeeded in reducing their systolic blood pressure by 8.1 mmHg and diastolic by 6.0 mmHg on average and 38% succeeded in reducing their blood pressure by one stage.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to HYPERTENSION